Preliminary report on activity and tolerability of epomediol, administered by intravenous infusion, in patients with chronic hepatopathies

J Int Med Res. 1988 May-Jun;16(3):237-43. doi: 10.1177/030006058801600312.


The therapeutic activity and tolerability of epomediol were studied in 28 patients with chronic hepatopathies. Treatment was continued, parenterally, for 10 days (400-600 mg once daily by intravenous infusion). Clinical parameters (headache, right hypochondrial pain, bitter taste in the mouth, asthenia and nausea) and hepatic function (transaminase, alkaline phosphatase and gamma-glutamyl transpeptidase) showed significant improvements. Clinical and systemic tolerabilities of epomediol were satisfactory.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Bridged Bicyclo Compounds, Heterocyclic
  • Chronic Disease
  • Clinical Trials as Topic
  • Drug Eruptions
  • Drug Tolerance
  • Female
  • Humans
  • Infusions, Intravenous
  • Liver Diseases / drug therapy*
  • Male
  • Middle Aged
  • Terpenes / adverse effects
  • Terpenes / therapeutic use*


  • Bridged Bicyclo Compounds, Heterocyclic
  • Terpenes
  • epomediol